open access

Vol 56, No 5 (2005)
Original paper
Submitted: 2013-02-15
Published online: 2006-05-28
Get Citation

Macroprolactin in subjects with hyperprolactinaemia: clinical observations and relations between free PRL and PRL complexed with IgG

Wojciech Jeske, Wojciech Zgliczyński, Krystyna Gorzelak
Endokrynol Pol 2005;56(5):779-784.

open access

Vol 56, No 5 (2005)
Original Paper
Submitted: 2013-02-15
Published online: 2006-05-28

Abstract

In some patients with hyperprolactinaemia a large portion of circulating prolactin is bound to authologous gammaglobulin and therefore it is called macroprolactin or Big-Big-Prolactin (BB-PRL). The aim of the study was to select patients with predominance of macroprolactin and to learn more about the natural course of this disorder, in particular about the possible dependence of the presence of clinical features from the amount of circulating “free” PRL level, and also to search whether the quantitative proportions of both forms of PRL are stable or they change parallel to changes of the total serum PRL level.
Material and methods We identified 58 patients with hyperprolactinaemia, in whom BB-PRL consisted ≥ 60% of the total PRL concentration. The predominance of macroprolactin was settled using the well accepted method of polyethylene glycol (PEG) precipitation of large m.w. serum proteins, followed by contemporary immunoradiometric measurement of the total and free PRL levels, and calculation of BB-PRL. Repeating such measurements during the long term observation lasting 6-66 months (mean 33 months), which was possible in 18 our patients (13 – with idiopathic hyperprolactinaemia and 5 – with pituitary adenoma), we could analyze the relations between both forms of PRL during the specific treatment, after it’s cessation and, in few cases – during pregnancy. Apart of that, in 18 patients selected from 53 with idiopathic hyperprolactinaemia, we analyzed the shortterm alterations in the ratio between free and complexed PRL during the metoclopramide PRL stimulation test.
Results and conclusions 1. In hyperprolactinaemic patients with predominance of BB-PRL, there was no direct correlation between the presence of clinical features and the concentration of residual “free” PRL. 2. During the long-term observation, in spite of moderate changes in the total PRL concentration induced by the treatment or it’s cessation (excluding pregnancy), the ratio of “free” PRL and BB-PRL remained stable. 3. During the short time of metoclopramide stimulation test, there was a marked rise mainly of the total and “free” PRL concentrations, and, in some tested subjects, the predominance of BB-PRL was lost temporally for 1 to 2 hours.

Abstract

In some patients with hyperprolactinaemia a large portion of circulating prolactin is bound to authologous gammaglobulin and therefore it is called macroprolactin or Big-Big-Prolactin (BB-PRL). The aim of the study was to select patients with predominance of macroprolactin and to learn more about the natural course of this disorder, in particular about the possible dependence of the presence of clinical features from the amount of circulating “free” PRL level, and also to search whether the quantitative proportions of both forms of PRL are stable or they change parallel to changes of the total serum PRL level.
Material and methods We identified 58 patients with hyperprolactinaemia, in whom BB-PRL consisted ≥ 60% of the total PRL concentration. The predominance of macroprolactin was settled using the well accepted method of polyethylene glycol (PEG) precipitation of large m.w. serum proteins, followed by contemporary immunoradiometric measurement of the total and free PRL levels, and calculation of BB-PRL. Repeating such measurements during the long term observation lasting 6-66 months (mean 33 months), which was possible in 18 our patients (13 – with idiopathic hyperprolactinaemia and 5 – with pituitary adenoma), we could analyze the relations between both forms of PRL during the specific treatment, after it’s cessation and, in few cases – during pregnancy. Apart of that, in 18 patients selected from 53 with idiopathic hyperprolactinaemia, we analyzed the shortterm alterations in the ratio between free and complexed PRL during the metoclopramide PRL stimulation test.
Results and conclusions 1. In hyperprolactinaemic patients with predominance of BB-PRL, there was no direct correlation between the presence of clinical features and the concentration of residual “free” PRL. 2. During the long-term observation, in spite of moderate changes in the total PRL concentration induced by the treatment or it’s cessation (excluding pregnancy), the ratio of “free” PRL and BB-PRL remained stable. 3. During the short time of metoclopramide stimulation test, there was a marked rise mainly of the total and “free” PRL concentrations, and, in some tested subjects, the predominance of BB-PRL was lost temporally for 1 to 2 hours.
Get Citation

Keywords

macroprolactin; BB-PRL; hyperprolactinaemia

About this article
Title

Macroprolactin in subjects with hyperprolactinaemia: clinical observations and relations between free PRL and PRL complexed with IgG

Journal

Endokrynologia Polska

Issue

Vol 56, No 5 (2005)

Article type

Original paper

Pages

779-784

Published online

2006-05-28

Page views

690

Article views/downloads

3372

Bibliographic record

Endokrynol Pol 2005;56(5):779-784.

Keywords

macroprolactin
BB-PRL
hyperprolactinaemia

Authors

Wojciech Jeske
Wojciech Zgliczyński
Krystyna Gorzelak

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl